Hypoxia inducible carbonic anhydrase IX, marker of tumor hypoxia, survival pathway and therapy target

Cell Cycle

Volumn 3, Issue 2, 2004, Pages 164-167

  Potter, Christian ^a   Harris, Adrian L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Carbonic anhydrase 9; Hypoxia; pH; Prognosis; Radiotherapy; Resistance; Therapy

Indexed keywords

ACETAZOLAMIDE; ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOENZYME; TUMOR MARKER; UNCLASSIFIED DRUG; CA9 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; ISOPROTEIN; MITOMYCIN; TRANSCRIPTION FACTOR; TUMOR ANTIGEN;

ACIDITY; ADAPTATION; ANIMAL CELL; CANCER SURVIVAL; CANCER THERAPY; CELL DEATH; CELL PH; DRUG POTENTIATION; ENZYME INHIBITION; GENE INDUCTION; GENE LOCATION; GENETIC STABILITY; HISTOCHEMISTRY; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; PROGNOSIS; PROTON TRANSPORT; REGULATORY MECHANISM; REVIEW; ANIMAL; CELL HYPOXIA; CELL STRAIN 3T3; CELL SURVIVAL; DRUG EFFECT; HELA CELL; METABOLISM; NEOPLASM; PH; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASES; CELL HYPOXIA; CELL SURVIVAL; HELA CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MITOMYCIN; NEOPLASMS; NIH 3T3 CELLS; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 2542601328     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Potter CP, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003; 89:2-7.
2. Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992; 187:620-6.
3. Pastorek J, Pastorekova S, Callebaut I, Mornon JP, Zelnik V, Opavsky R, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994; 9:2877-88.
4. Wingo T, Tu C, Laipis PJ, Silverman DN. The catalytic properties of human carbonic anhydrase IX. Biochem Biophys Res Commun 2001; 288:666-9.
5. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich, G, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001; 158:905-19.
6. Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastorekova S, Pastorek J, et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 1998; 153:279-85.
7. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60:7075-83.
8. Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE, et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998; 95:12596-601.
9. Kaluzova M, Pastorekova S, Svastova E, Pastorek J, Stanbridge EJ, Kaluz S. Characterization of the MN/CA 9 promoter proximal region: A role for specificity protein (SP) and activator protein 1 (API) factors. Biochem J 2001; 359:669-77.
10. Kaluzova M, Pastorekova S, Pastorek J, Kaluz S. P53 tumor suppressor modulates transcription of the TATA-less gene coding for the tumor-associated carbonic anhydrase MN/CA IX in MaTu cells. Biochim Biophys Acta 2000; 1491:20-6.
11. Cho M, Uemura H, Kim SC, Kawada Y, Yoshida K, Hirao Y, et al. Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma. Br J Cancer 2001; 85:563-7.
12. Ashida S, Nishimori I, Tanimura M, Onishi S, Shuin T. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma. J Cancer Res Clin Oncol 2002; 128:561-8.
13. Beasley NJ, Wykoff CC, Watson PH, Leek R, Turley H, Gatter K, et al. Carbonic anhydrase DC, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001; 61:5262-7.
14. Olive PL, Aquino-Parsons C, MacPhail SH, Liao SY, Raleigh JA, Lerman MI, et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 2001; 61:8924-9.
15. Turner KJ, Crew JP, Wykoff CC, Watson PH, Poulsom R, Pastorek J et al. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer 2002; 86:1276-82.
16. Wykoff CC, Beasley N, Watson PH, Campo L, Chia SK, English R, et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 2001; 158:1011-9.
17. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001; 61:6394-9.
18. Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD, et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding. Int J Cancer 2003; 104:85-91.
19. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase ix, in invasive breast carcinoma. J Clin Oncol 2001; 19:3660-8.
20. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in nonsmall cell lung cancer. Cancer Res 2001; 61:7992-8.
21. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase DC, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002; 8:2595-604.
22. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001; 7:3399-403.
23. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, et al. Carbonic anhydrase DC expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in nonsmall-cell lung cancer. J Clin Oncol 2003; 21:473-82.
24. Schmaltz C, Hardenbergh PH, Wells A, Fisher DE. Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol 1998; 18:2845-54.
25. Zanke BW, Lee C, Arab S, Tannock IF. Death of tumor cells after intracellular acidification is dependent on stress-activated protein kinases (SAPK/JNK) pathway activation and cannot be inhibited by Bcl-2 expression or interleukin 1beta-converting enzyme inhibition. Cancer Res 1998; 58:2801-8.
26. Yamagata M, Hasuda K, Stamato T, Tannock IF. The contribution of lactic acid to acidification of tumors: Studies of variant cells lacking lactate dehydrogenase. Br J Cancer 1998; 77:1726-31.
27. 2 modulates intracellular pH, intracellular oxidant generation, and interleukin-8 secretion in human neutrophils. J Leukoc Biol 2002; 71:603-10.
28. Helmlinger G, Sckell A, Dellian M, Forbes NS, Jam RK. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 2002; 8:1284-91.
29. Griffiths JR, McIntyre DJ, Howe FA, Stubbs M. Why are cancers acidic? A carrier-mediated diffusion model for H+ transport in the interstitial fluid. Novartis Found Symp 2001; 240:46-62; discussion 62-47, 152-3.
30. Karumanchi SA, Jiang L, Knebelmann B, Stuart-Tilley AK, Alper SL, Sukhatme VP. VHL tumor suppressor regulates Cl-/HCO3-exchange and Na+/H+ exchange activities in renal carcinoma cells. Physiol Genomics 2001; 5:119-28.
31. Vaughan-Jones RD, Spitzer KW. Role of bicarbonate in the regulation of intracellular pH in the mammalian ventricular myocyte. Biochem Cell Biol 2002; 80:579-96.
32. Gut MO, Parkkila S, Vernerova Z, Rohde E, Zavada J, Hocker M, et al. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 2002; 123:1889-903.
33. Zavada J, Zavadova Z, Pastorek J, Biesova Z, Jezek J, Velek J. Human tumor-associated cell adhesion protein MN/CA IX: Identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer 2000; 82:1808-13.
34. Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, et al. Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. J Clin Oncol 1993; 11:738-50.
35. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997; 15:1529-37.
36. Loh A, Sgouros G, O'Donoghue JA, Deland D, Puri D, Capitelli P, et al. Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients. J Nucl Med 1998; 39:484-9.
37. Durrbach A, Angevin E, Poncet P, Rouleau M, Chavanel G, Chapel A, et al. Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro. Cancer Gene Ther 1999; 6:564-71.
38. Steffens MG, Boerman OC, de Muldér PH, Oyen WJ, Buijs WC, Witjes JA, et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999; 5:3268s-74s.
39. Chrastina A, Pastorekova S, Pastorek J. Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by (125)I-labeled M75 monoclonal antibody. Neoplasma 2003; 50:13-21.
40. Vissers JL, De Vries IJ, Engelen LP, Scharenborg NM, Molkenboer J, Figdor CG, et al. Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes. Int J Cancer 2002; 100:441-4.
41. Hernandez JM, Bui MH, Han KR, Mukouyama H, Freitas DG, Nguyen D, et al. Novel Kidney Cancer Immunotherapy Based on the Granulocyte- Macrophage Colony-stimulating Factor and Carbonic Anhydrase DC Fusion Gene. Clin Cancer Res 2003; 9:1906-1916.
42. Teicher BA, Liu SD, Liu JT, Holden SA, Herman TS. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res 1993; 13:1549-56.
43. Tannock IF. Tumor physiology and drug resistance. Cancer Metastasis Rev 2001; 20:123-32.
44. Parkkila S, Rajaniemi H, Parkkila AK, Kivela J, Waheed A, Pastorekova S, et al. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci USA 2000; 97:2220-4.
45. Parker CA, Jaffar M, Williams K, Robertson N, Harris AL, Stratford I. Inhibition of CA-IX modulates toxicity of mitomycin C in anoxic tumor cell lines. Proceedings of the AACR 2003; R1637.
46. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003; 23:146-89.
47. Supuran CT, Briganti F, Tilli S, Chegwidden WR, Scozzafava A. Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents? Bioorg Med Chem 2001; 9:703-14.